ISRG
SP100NasdaqGSIntuitive Surgical, Inc.
Healthcare · Medical Instruments & Supplies · United States
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
www.intuitive.com ↗Shares trade at a premium 51.8× trailing earnings, easing to 36.1× on forward estimates. Profitability shows a net margin of 28.2% and return on equity of 17.2%. Revenue grew 23.0% year-on-year. The mean analyst target of USD565.08 sits 32.6% above the current price (no rating, 29 analysts).
business model
Intuitive Surgical develops, manufactures, and markets robotic-assisted surgical systems, most notably the da Vinci platform for minimally invasive surgery and the Ion system for lung biopsy. Its business combines high-value system placements with a recurring razor-and-blade model of instruments, accessories, and service contracts tied to procedure volumes.
revenue segments
Revenue comes from Instruments & Accessories (consumables used in each procedure, the largest and most recurring source), Systems (sales and leasing of da Vinci and Ion platforms), and Services (maintenance, support, and training). Recurring instruments and services make up the majority of revenue.
key dependencies
The company depends on growth in robotic-assisted procedure volumes, hospital capital budgets for system purchases, regulatory clearances for new systems and indications (e.g., da Vinci 5), reimbursement policies, surgeon training and adoption, and its installed base of systems that drives consumable pull-through.
competitors
Competitors include Medtronic (Hugo robotic system), Johnson & Johnson MedTech (Ottava and Monarch), Stryker, and CMR Surgical, plus conventional laparoscopic and open-surgery approaches.
moat
Intuitive's moat rests on a large global installed base with high switching costs, extensive clinical data and surgeon training networks, a broad instrument/accessory ecosystem, strong patents, regulatory clearances, and recurring per-procedure revenue that compounds as procedures grow.
risks
Risks include intensifying competition from large medtech entrants, hospital capital-spending cyclicality, regulatory and reimbursement changes, product-liability and safety scrutiny, dependence on procedure-volume growth, and high valuation sensitivity to growth expectations.
Financials & metrics
as of 28 Aug 2026Price is closer to the low end of its range. Green = nearer the yearly low, red = nearer the high — a position indicator, not a buy/sell signal.
Tap any metric for an explanation.● provider● computedN/A not available from source
Valuation history is being recorded
We snapshot P/E and price targets daily. This chart fills in over the coming days.
Full financial statements
Income statement
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | $10.06B | $8.35B | $7.12B | $6.22B | — |
| Cost of revenue | $3.42B | $2.72B | $2.39B | $2.03B | — |
| Gross profit | $6.64B | $5.63B | $4.73B | $4.20B | — |
| Operating expense | $3.70B | $3.29B | $2.96B | $2.62B | — |
| R&D | $1.31B | $1.15B | $998.80M | $879.00M | — |
| Operating income | $2.95B | $2.35B | $1.77B | $1.58B | — |
| Pretax income | $3.31B | $2.67B | $1.96B | $1.61B | — |
| Tax provision | $434.80M | $336.30M | $141.60M | $262.40M | — |
| Net income | $2.86B | $2.32B | $1.80B | $1.32B | — |
| EBITDA | $3.62B | $2.85B | $2.22B | $1.94B | — |
| Diluted EPS | $7.87 | $6.42 | $5.03 | $3.65 | — |
Balance sheet
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $20.46B | $18.74B | $15.44B | $12.97B | — |
| Current assets | $9.78B | $7.11B | $7.89B | $6.25B | — |
| Cash & equivalents | $3.37B | $2.03B | $2.75B | $1.58B | — |
| Inventory | $1.84B | $1.49B | $1.22B | $893.20M | — |
| Total liabilities | $2.52B | $2.21B | $2.04B | $1.86B | — |
| Current liabilities | $2.01B | $1.75B | $1.66B | $1.42B | — |
| Total debt | — | — | — | — | $87.00M |
| Shareholders' equity | $17.82B | $16.43B | $13.31B | $11.04B | — |
| Retained earnings | $7.01B | $6.80B | $4.74B | $3.50B | — |
| Working capital | $7.77B | $5.37B | $6.23B | $4.83B | — |
Cash flow
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $3.03B | $2.42B | $1.81B | $1.49B | — |
| Investing cash flow | $665.80M | -$3.27B | -$360.10M | $1.37B | — |
| Financing cash flow | -$2.36B | $150.90M | -$287.60M | -$2.57B | — |
| Capital expenditure | -$539.80M | -$1.11B | -$1.06B | -$532.40M | -$339.50M |
| Free cash flow | $2.49B | $1.30B | $749.60M | $958.40M | — |
| Share buybacks | -$2.30B | $0.00 | -$416.30M | -$2.61B | — |
| End cash position | $3.41B | $2.06B | $2.77B | $1.60B | — |
Reported figures from public filings via Yahoo Finance. Line coverage varies by company. Not investment advice.
Dividends
This company does not currently pay a dividend.
Analyst assessment
as of 28 Aug 2026Aggregate consensus only. Named per-analyst targets require a premium source and are not shown; the data model is ready to hold them if one is added.
Technicals
as of 27 Aug 2026News
Sector peers
Notes & alerts
Sign in to keep a private research note and set price alerts for ISRG.